Investigational antibody drug conjugates for solid tumors

Bibliography

• Presta LG. Selection, design, and engineering of therapeutic antibodies. J Allergy Clin Immunol 2005;116:731-6; quiz 737
   PubMed Web of Science ®Google Scholar
• Wu A.M, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23:1137-46
   PubMed Web of Science ®Google Scholar
• Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008;14:154-69
   PubMed Web of Science ®Google Scholar
• Kim KM, McDonagh CF, Westendorf L, Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol Cancer Ther 2008;7:2486-97
   PubMed Web of Science ®Google Scholar
• Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010;9:790-803
   PubMed Web of Science ®Google Scholar
• Francisco JA, Cerveny CG, Meyer DL, cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458-65
   PubMed Web of Science ®Google Scholar
• Doronina SO, Toki BE, Torgov MY, Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-84
   PubMed Web of Science ®Google Scholar
• Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 2010;14:529-37
   PubMed Web of Science ®Google Scholar
• Gerber HP. Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma. Biochem Pharmacol 2010;79:1544-52
   PubMed Web of Science ®Google Scholar
• Oflazoglu E, Stone IJ, Gordon K, Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res 2008;14:6171-80
   PubMed Web of Science ®Google Scholar
• Widdison WC, Wilhelm SD, Cavanagh EE, Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 2006;49:4392-408
   PubMed Web of Science ®Google Scholar
• Krop IE, Beeram M, Modi S, Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010;28:2698-704
   PubMed Web of Science ®Google Scholar
• Erickson HK, Park PU, Widdison WC, Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006;66:4426-33
   PubMed Web of Science ®Google Scholar
• Krop I, LoRusso P, Miller KD, A phase II study of trastuzumab-DM1 (T-DM1), a novel HER2 antibody-drug conjugate, in patients withHER2+ metastatic breast cancer who were previously treated with an anthracyclin, a taxane, capecitabine, lapatinib, and trastuzumab. In San Antonio Breast Cancer Symposium; San Antonio; 2009
   Google Scholar
• Erickson HK, Widdison WC, Mayo MF, Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 2010;21:84-92
   PubMed Web of Science ®Google Scholar
• Law CL, Gordon KA, Toki BE, Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res 2006;66:2328-37
   PubMed Web of Science ®Google Scholar
• Pollack VA, Alvarez E, Tse KF, Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol 2007;60:423-35
   PubMed Web of Science ®Google Scholar
• Tse KF, Jeffers M, Pollack VA, CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 2006;12:1373-82
   PubMed Web of Science ®Google Scholar
• Hwu P, Sznol M, Pavlick H, A phase I/II study of CRO11-vcMMAE, an antibody-drug conjugate (ADC) targeting glycoprotein NMB (GPNMB) in patients (pts) with advanced melanoma. J Clin Oncol 2009;27(15S): ASCO Meeting Abstract 9032
   Google Scholar
• Burris H, Saleh M, Bendell J, A phase I/II study of CRO11-vcMMAE (CDX-011), an antibody-drug conjugate, in patients with locally advanced or metastatic breast cancer. In 32nd Annual San Antonio Breast Cancer Symposium; San Antonio, TX; 2009
   Google Scholar
• Kuroda K, Liu H, Kim S, Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Prostate 2009;69:1579-85
   PubMed Web of Science ®Google Scholar
• Ma D, Hopf CE, Malewicz AD, Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res 2006;12:2591-6
   PubMed Web of Science ®Google Scholar
• Gruss HJ, Kadin M.E. Pathophysiology of Hodgkin's disease: functional and molecular aspects. Baillieres Clin Haematol 1996;9:417-46
   PubMed Web of Science ®Google Scholar
• Hsu SM, Waldron J, Xie SS, Hsu PL. Hodgkin's disease and anaplastic large cell lymphoma revisited. 1. unique cytokine and cytokine receptor profile distinguished from that of non-hodgkin's lymphomas. J Biomed Sci 1995;2:302-13
   PubMedGoogle Scholar
• Diegmann J, Junker K, Gerstmayer B, Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, real-time RT-PCR and immunohistochemistry. Eur J Cancer 2005;41:1794-801
   PubMed Web of Science ®Google Scholar
• Adam PJ, Terrett JA, Steers G, CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. Br J Cancer 2006;95:298-306
   PubMed Web of Science ®Google Scholar
• Junker K, Hindermann W, von Eggeling F, CD70: a new tumor specific biomarker for renal cell carcinoma. J Urol 2005;173:2150-3
   PubMed Web of Science ®Google Scholar
• Hishima T., Fukayama M, Hayashi Y, CD70 expression in thymic carcinoma. Am J Surg Pathol 2000;24:742-6
   PubMed Web of Science ®Google Scholar
• Agathanggelou A, Niedobitek G, Chen R, Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells. Am J Pathol 1995;147:1152-60
   PubMed Web of Science ®Google Scholar
• Held-Feindt J, Mentlein R. CD70/CD27 ligand, a member of the TNF family, is expressed in human brain tumors. Int J Cancer 2002;98:352-6
   PubMed Web of Science ®Google Scholar
• Hintzen RQ, Lens SM, Koopman G, CD70 represents the human ligand for CD27. Int Immunol 1994;6:477-80
   PubMed Web of Science ®Google Scholar
• Ansell SM, Thomposon J, Infante J, Targeting CD70 in non-Hodgkin lymphoma and renal cell carcinoma: a phase 1 study of the antibody-drug conjugate SGN-75. In 35th ESMO Congress; 2010
   Google Scholar
• Gudas JM, An Z, Morrison RK, ASG-5ME: a novel antibody-drug conjugate (ADC) therapy for prostate, pancreatic, and gastric cancers. In 2010 Annual Asco Meeting, Genitourinary Cancers Symposium; 2010
   Google Scholar
• Gudas JM, Torgov M, An Z, Use of AGS-16M8F as a novel antibody drug conjugate (ADC) for treating renal cancers. J Clin Oncol 2010;28:Suppl.518-27
   Google Scholar
• Petrul H, Ranges G, Bouret E, In vitro and in vivo efficacy of the anti-MN immunoconjugate BAY 79-4620, MN-IC, in MN (CAIX) expressing preclinical tumor models. In AACR Meeting; Washington, DC; 2010
   Google Scholar
• Schatz C, Pena CE, Petrul H, Efficacy and candidate biomarker evaluation for the anti-MN immunoconjugate BAY 79-4620, MN-IC in MN (CAIX) positive preclinical xenograft models. In AACR; Washington, DC; 2010
   Google Scholar
• Bianco C, Rangel MC, Castro NP, Role of Cripto-1 in stem cell maintenance and malignant progression. Am J Pathol 2010;177:532-40
   PubMed Web of Science ®Google Scholar
• Bianco C, Strizzi L, Normanno N, Cripto-1: an oncofetal gene with many faces. Curr Top Dev Biol 2005;67:85-133
   PubMed Web of Science ®Google Scholar
• Bianco C, Cotten C, Lonardo E, Cripto-1 is required for hypoxia to induce cardiac differentiation of mouse embryonic stem cells. Am J Pathol 2009;175:2146-58
   PubMed Web of Science ®Google Scholar
• Campisi I, Granata OM, Cocciadiferro L, 16alpha-hydroxyestrone inhibits estrogen sulfotransferase activity in human liver cancer cells. Ann NY Acad Sci 2009;1155:237-41
   PubMed Web of Science ®Google Scholar
• Cocciadiferro L, Micli V, Kang KS, Profiling cancer stem cells in androgen-responsive and refractory human prostate tumor cell lines. Ann NY Acad Sci 2009;1155:257-62
   PubMed Web of Science ®Google Scholar
• Watanabe K, Meyer MJ, Strizzi L, Cripto-1 is a cell surface marker for a tumorigenic, undifferentiated subpopulation in human embryonal carcinoma cells. Stem Cells 2010;28:1303-14
   PubMed Web of Science ®Google Scholar
• Glaser S, Van Vlijmen H., Lugovskoy A.A. & Sanicola-Nadel M. Cripto binding molecules. (ed. U.P. Application). 2010
   Google Scholar
• Krop IE, Beeram M, Modi S, Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010;28:2698-704
   PubMed Web of Science ®Google Scholar
• Lewis Phillips GD, Li G, Dugger DL, Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-90
   PubMed Web of Science ®Google Scholar
• Lewis Phillips GD, Fields CT, Crocker L, Potent anti-tumor activity of trastuzumab-DM1 antibody-drug conjugate in combination with cytotoxic chemotherapeutic agents, antibodies or small molecule kinase inhibitors. In AACR Annual Meeting; 2008
   Google Scholar
• Beeram M, Burris HA, Modi S, A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC). In ASCO Annual Meeting; 2008
   Google Scholar
• Holden SN, Beeram M, Krop IE, A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients with advanced HER2+ breast cancer. J Clin Oncol Suppl 2008;22:4711-17
   Google Scholar
• Burris HA III, Rugo HS, Vukelja SJ, Phase II study of the antibody drug conjugate trastuzumab-dm1 for the treatment of human epidermal growth factor receptor 2 (HER2) -positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2010;29:5865-72
   Google Scholar
• Vogel CL, Burris HA, Limcatani S, A phase II study of trastuzumab-DM1 (T-DM1), a HER-2 antibody-drug conjugate (ADC), in patients (pts) with HER-2 metastatic breast cancer (MBC): final results. In ASCO Annual Meeting; 2009
   Google Scholar
• LoRusso PM, Girish S, Burris HA, Population pharmacokinetics of Trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate given every 3 weeks (q3W) or weekly (qw) to patients with HER2-positive metastatic breast cancer (MBC). Cancer Res 2009;69: abstract Nr 5099
   Web of Science ®Google Scholar
• Burris HA, Vukelja S, Krop IE, Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and phase II trial results. EJC Suppl 2010;53:213-14
   Google Scholar
• Vater CA, Manning C, Millar H, McCabe F. Anti-tumor efficacy of the integrin-targeted immunoconjugate IMGN388 in preclinical models. Eur J Cancer 2008;6(Suppl): abstract 529
   Google Scholar
• Thompson DS, Patnaik JC, Bendell K, A phase I dose-escalation study of IMGN388 in patients with solid tumors J Clin Oncol. 2010;28: abstract 3058
   Google Scholar
• Tassone P, Gozzini A, Goldmacher V, In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res 2004;64:4629-36
   PubMed Web of Science ®Google Scholar
• Woll P, Lorigan PJ, O'Brien M. Clinical experience of IMGN901 (BB-10901, huN901-DM1) in patients with Merkel cell carcinoma (MCC). In AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther; Boston; 2009
   Google Scholar
• McCann J, Fossella FV, Viallalona-Calero MA. Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small cell carcinoma. J Clin Oncol 2007;15:2765-72
   Google Scholar
• Fosella F, Woll PJ, Lorigan PJ. Clinical experience of IMGN901 (BB-10901) in patients with small cell lung carcinoma. J Thorac Oncol 2009;4: abstract PD4.3.5
   Google Scholar
• Diegmann J, Junker K, Loncarevic IF, Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes. Neoplasia 2006;8:933-8
   PubMed Web of Science ®Google Scholar
• Cardarelli P, King D, Terrett J, Efficacy and safety of a human anti-CD70 antibody-MGBA conjugate. In AACR Annual Meeting 2008; 2008
   Google Scholar
• Terrett J, Gangwar S, Rao-Naik C, Single, low dose treatment of lymphoma and renal cancer xenografts with human anti-CD70 antibody-toxin conjugates, results in long term cures. In AACR Annual Meeting 2007; 2007
   Google Scholar
• Lyon RP, Ryan MC, Kostner H, Conjugation and assay methodologies to screen for antibodies with optimal properties for use as antibody-drug conjugate. In AACR; Washington, DC; 2010
   Google Scholar
• Zhou BB, Zhang H, Damelin M, Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009;8:806-23
   PubMed Web of Science ®Google Scholar
• Junutula JR, Flagella KM, Graham RA, Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res 2010;16:4769-78
   PubMed Web of Science ®Google Scholar
• Junutula JR, Raab H, Clark S, Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008;26:925-32
   PubMed Web of Science ®Google Scholar
• Henderson LA, Baynes JW, Thorpe SR. Identification of the sites of IgG catabolism in the rat. Arch Biochem Biophys 1982;215:1-11
   PubMedGoogle Scholar
• Moldoveanu Z, Epps JM, Thorpe SR, Mestecky J. The sites of catabolism of murine monomeric IgA. J Immunol 1988;141:208-13
   PubMed Web of Science ®Google Scholar
• Ferl GZ, Kenanova V, Wu AM, DiStefano JJ III. A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Mol Cancer Ther 2006;5:1550-8
   PubMed Web of Science ®Google Scholar
• Alley SC, Zhang X, Okeley NM, The pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther 2009;330:932-8
   PubMed Web of Science ®Google Scholar
• Rybak JN, Trachsel E, Scheuermann J, Neri D. Ligand-based vascular targeting of disease. ChemMedChem 2007;2:22-40
   PubMed Web of Science ®Google Scholar
• Scott AM, Lee FT, Tebbutt N, A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci USA 2007;104:4071-6
   PubMed Web of Science ®Google Scholar
• Zahnd C, Kawe M, Stumpp MT, Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res 2010;70:1595-605
   PubMed Web of Science ®Google Scholar
• Stohrer M, Boucher Y, Stangassinger M, Jain RK. Oncotic pressure in solid tumors is elevated. Cancer Res 2000;60:4251-5
   PubMed Web of Science ®Google Scholar
• Weinstein JN van Osdol W. The macroscopic and microscopic pharmacology of monoclonal antibodies. Int J Immunopharmacol 1992;14:457-63
   PubMed Web of Science ®Google Scholar